Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Hongjing ZangGuoqing QianDan ZongSongqing FanTaofeek K OwonikokoSuresh R RamalingamShi-Yong SunPublished in: Cancer (2020)
The current findings provide strong preclinical evidence in support of the potential for LBH589 to overcome osimertinib resistance in the clinic.